Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.39 -0.4%	$2.29	$0.40 ▼ $3.10	$192.68M	2.05	2.21 million shs	965,065 shs
EDIT Editas Medicine	$2.84 +3.3%	$2.06	$0.91 ▼ $5.91	$237.75M	2.15	2.64 million shs	2.56 million shs
LEGN Legend Biotech	$39.75 +0.4%	$33.24	$27.34 ▼ $60.87	$7.30B	0.19	1.37 million shs	1.99 million shs
SRPT Sarepta Therapeutics	$18.38 +0.9%	$29.52	$16.88 ▼ $150.48	$1.81B	0.45	2.31 million shs	12.02 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+0.42%	0.00%	-12.73%	+281.13%	+70.21%
EDIT Editas Medicine	-3.51%	-3.85%	+39.59%	+116.54%	-50.98%
LEGN Legend Biotech	+0.38%	+5.60%	+7.49%	+18.32%	-26.67%
SRPT Sarepta Therapeutics	-5.30%	-4.31%	-49.67%	-66.24%	-88.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.1513 of 5 stars	3.5	1.0	4.7	2.4	1.7	1.3
EDIT Editas Medicine	4.2238 of 5 stars	3.2	2.0	4.3	3.7	2.5	0.6
LEGN Legend Biotech	3.3699 of 5 stars	4.5	3.0	0.0	2.1	1.7	0.6
SRPT Sarepta Therapeutics	4.7294 of 5 stars	4.2	2.0	4.2	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	123.15% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	65.49% Upside
LEGN Legend Biotech	2.90	Moderate Buy	$73.33	84.49% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$58.54	218.51% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00 ➝ $81.00
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
7/8/2025	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
7/2/2025	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00 ➝ $54.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$147.56M	1.31	$0.36 per share	6.60	($0.01) per share	-239.00
EDIT Editas Medicine	$35.84M	6.63	N/A	N/A	$1.63 per share	1.74
LEGN Legend Biotech	$627.24M	11.65	N/A	N/A	$5.70 per share	6.97
SRPT Sarepta Therapeutics	$1.90B	0.95	$2.33 per share	7.89	$15.99 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.98	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
LEGN Legend Biotech	-$177.03M	-$0.59	N/A	N/A	N/A	-29.95%	-21.19%	-13.47%	8/8/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.68	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest SRPT, CTMX, EDIT, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	LEGN Legend Biotech	-$0.18	N/A	N/A	N/A	$237.49 million	N/A
8/6/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
EDIT Editas Medicine	N/A	3.08	3.08
LEGN Legend Biotech	0.30	5.20	5.07
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
LEGN Legend Biotech	70.89%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EDIT Editas Medicine	1.90%
LEGN Legend Biotech	0.02%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
LEGN Legend Biotech	2,609	183.76 million	183.73 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

SRPT, CTMX, EDIT, and LEGN Headlines

Recent News About These Companies

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

1 hour ago | globenewswire.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SRPT

2 hours ago | theglobeandmail.com

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

2 hours ago | bostonglobe.comB

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

2 hours ago | biopharmadive.comB

Sarepta Therapeutics makes layoffs after gene therapy setback

2 hours ago | bizjournals.com

JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

2 hours ago | msn.com

Sarepta Therapeutics stock soars after strategic restructuring plan unveiled

2 hours ago | investing.com

Sarepta to cut 500 jobs after gene therapy setback, shares jump

2 hours ago | msn.com

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

2 hours ago | msn.com

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

2 hours ago | finance.yahoo.com

Sarepta Therapeutics rises after restructuring, pipeline focus

2 hours ago | msn.com

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

3 hours ago | benzinga.com

Sarepta Therapeutics (SRPT) Reports Q2 SG&A Expenses | SRPT Stock News

4 hours ago | gurufocus.com

Sarepta to cut 500 jobs after gene therapy setback

4 hours ago | reuters.com

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

4 hours ago | businesswire.com

Kessler Topaz Meltzer & Check, LLP Notifies Sarepta Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

5 hours ago | globenewswire.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 16 at 11:13 AM | globenewswire.com

Sarepta Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 â€“ SRPT

July 16 at 9:20 AM | globenewswire.com

Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients

July 15 at 1:55 PM | msn.com

Faruqi & Faruqi Reminds Sarepta Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025 - SRPT

July 15 at 10:43 AM | prnewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.7% - Should You Buy?

July 14 at 12:30 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
By Leo Miller | July 8, 2025
View EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
Capitalize on Volatility: 3 Finance Stocks Thriving in 2025
By Chris Markoch | July 2, 2025
View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025

SRPT, CTMX, EDIT, and LEGN Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.39 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.44 +0.05 (+2.09%)

As of 07:37 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.84 +0.09 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 -0.02 (-0.67%)

As of 07:56 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Legend Biotech NASDAQ:LEGN

$39.75 +0.16 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$39.61 -0.14 (-0.35%)

As of 06:49 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sarepta Therapeutics NASDAQ:SRPT

$18.38 +0.17 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$24.65 +6.27 (+34.13%)

As of 08:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time